Dr. Linda Pilarski is a professor in the Department of Oncology at the Cross Cancer Institute, University of Alberta, and is cross-appointed in the Department of Medical Microbiology and Immunology.
Major areas of her research are the characterization of the malignant clone in multiple myeloma, the mechanisms of malignant invasion and spread, and the nature of drug resistance in myeloma. Her lab is also involved in investigating the mechanistic basis for mobilization of stem cells used autologous or allogeneic hematopoietic transplantation.
She obtained her BSc at Elmhurst College, ILL. USA and her Ph.D. from the University of Adelaide, South Australia. She has over 118 publications in scientific journals. In addition to serving on the Scientific Advisory Board of the International Myeloma Foundation, she is currently President of the Canadian Society for Immunology, a member of the American Society for Hematology, serves on the Board of Directors for the Canadian Federation of Biological Sciences and on the Board of Directors of the Edmonton and Northwest Territories Unit of the Canadian Cancer Society.
Her research is funded by the National Cancer Institute of Canada, the Medical Research Council of Canada, the Leukemia Research Fund, the Cancer Research Society, the Alberta Cancer Foundation and the Alberta Cancer Board Research Initiatives Program. She works in close collaboration with Dr. Andrew Belch to carry out a bench to bedside translational research program in myeloma.